Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials.
Willa D BrenowitzKristine YaffePublished in: Nature reviews. Neurology (2022)
Recent high-profile failures of Alzheimer disease treatments at the clinical trial stage have led to renewed efforts to identify and test novel interventions for Alzheimer disease and related dementias (ADRD). In this Perspective, we highlight the importance of including well-designed observational studies as part of these efforts. Observational research is an important cornerstone for gathering evidence on risk factors and causes of ADRD; this evidence can then be combined with data from preclinical studies and randomized controlled trials to inform the development of effective interventions. Observational study designs can be particularly beneficial for hypothesis generation, posing questions that are unethical or impractical for a trial setting, studying life-course associations, research in populations typically not included in trials, and public health surveillance. Here, we discuss each of these situations in the specific context of ADRD research. We also highlight novel approaches to enhance causal inference and provide a timely discussion on how observational epidemiological studies help provide a bridge between preclinical studies and successful interventions for ADRD.
Keyphrases
- clinical trial
- public health
- case control
- risk factors
- mild cognitive impairment
- physical activity
- phase ii
- cell therapy
- study protocol
- phase iii
- cross sectional
- systematic review
- mesenchymal stem cells
- machine learning
- single cell
- big data
- bone marrow
- deep learning
- data analysis
- artificial intelligence
- genetic diversity